Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants

Majerová-Uhlíková T, Dantuma NP, Lindsten K, Masucci MG, Konvalinka J.

. 2006 ; 36 (1) : 50-59.

Jazyk angličtina Země Nizozemsko

Typ dokumentu srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc07521927

Grantová podpora
NR8571 MZ0 CEP - Centrální evidence projektů

BACKGROUND: The introduction of HIV proteinase inhibitors (PIs) as anti-AIDS drugs resulted in decreased mortality and prolonged life expectancy of HIV-positive patients. However, rapid selection of drug-resistant HIV variants is a common complication in patients undergoing highly active anti-retroviral therapy (HAART). Thus, monitoring of clinical resistance development is indispensable for rational pharmacotherapy. OBJECTIVE: We present a non-infectious cell-based assay for drug resistance quantification of HIV proteinase (PR) - an important target of HAART. STUDY DESIGN: Previously, we showed [Lindsten K, Uhlikova T, Konvalinka J, Masucci MG, Dantuma NP. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob Agents Chemother 2001;45:2616-22] that the expression of a fusion protein (GFP-PR), comprised of HIV-1 proteinase wild-type artificial precursor (PR) and green fluorescent protein (GFP), in transiently transfected tissue culture cells depends on the presence of PR-specific inhibitors (PIs). Here we show that in the GFP-PR reporter the HIV wild-type PR can be replaced by a drug-resistant HIV PR mutant, yielding a simple and biologically relevant tool for the quantitative analysis of drug-resistant HIV PR mutants susceptibility to HIV proteinase inhibitors. RESULTS: We cloned a set of GFP-PR reporters, some of which possess a simple, well-defined drug-resistant PR mutant (G48V L90M, V82A, A71V V82T I84V, D30N, K45I); another four complex PR mutants were obtained from patients undergoing HAART. The results were compared with genotyping and enzyme kinetics data. Furthermore, we designed a single inhibitor concentration experiment setup for easy evaluation of drug resistance profiles for mutants of interest. The resistance profiles clearly demonstrate the importance of succession of individual drugs during the treatment for drug resistance development. CONCLUSION: We show that the GFP-PR assay might serve as a non-infectious, rapid, cheap, and reliable alternative to the currently used phenotypic assays.

Citace poskytuje Crossref.org

000      
00000naa 2200000 a 4500
001      
bmc07521927
003      
CZ-PrNML
005      
20131014125828.0
008      
090423s2006 ne e eng||
009      
AR
024    __
$a 10.1016/j.jcv.2006.01.014 $2 doi
035    __
$a (PubMed)16527535
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Majerová, Taťána $7 xx0157008
245    10
$a Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants / $c Majerová-Uhlíková T, Dantuma NP, Lindsten K, Masucci MG, Konvalinka J.
314    __
$a Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo 2, 166 10 Praha 6, Czech Republic
520    9_
$a BACKGROUND: The introduction of HIV proteinase inhibitors (PIs) as anti-AIDS drugs resulted in decreased mortality and prolonged life expectancy of HIV-positive patients. However, rapid selection of drug-resistant HIV variants is a common complication in patients undergoing highly active anti-retroviral therapy (HAART). Thus, monitoring of clinical resistance development is indispensable for rational pharmacotherapy. OBJECTIVE: We present a non-infectious cell-based assay for drug resistance quantification of HIV proteinase (PR) - an important target of HAART. STUDY DESIGN: Previously, we showed [Lindsten K, Uhlikova T, Konvalinka J, Masucci MG, Dantuma NP. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob Agents Chemother 2001;45:2616-22] that the expression of a fusion protein (GFP-PR), comprised of HIV-1 proteinase wild-type artificial precursor (PR) and green fluorescent protein (GFP), in transiently transfected tissue culture cells depends on the presence of PR-specific inhibitors (PIs). Here we show that in the GFP-PR reporter the HIV wild-type PR can be replaced by a drug-resistant HIV PR mutant, yielding a simple and biologically relevant tool for the quantitative analysis of drug-resistant HIV PR mutants susceptibility to HIV proteinase inhibitors. RESULTS: We cloned a set of GFP-PR reporters, some of which possess a simple, well-defined drug-resistant PR mutant (G48V L90M, V82A, A71V V82T I84V, D30N, K45I); another four complex PR mutants were obtained from patients undergoing HAART. The results were compared with genotyping and enzyme kinetics data. Furthermore, we designed a single inhibitor concentration experiment setup for easy evaluation of drug resistance profiles for mutants of interest. The resistance profiles clearly demonstrate the importance of succession of individual drugs during the treatment for drug resistance development. CONCLUSION: We show that the GFP-PR assay might serve as a non-infectious, rapid, cheap, and reliable alternative to the currently used phenotypic assays.
650    _2
$a monoklonální protilátky $x metabolismus $7 D000911
650    _2
$a biotest $x metody $7 D001681
650    _2
$a western blotting $7 D015153
650    _2
$a klonování DNA $7 D003001
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a virová léková rezistence $7 D024882
650    _2
$a hodnotící studie jako téma $7 D005069
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a fluorometrie $7 D005470
650    _2
$a reportérové geny $7 D017930
650    _2
$a virové geny $7 D005814
650    _2
$a zelené fluorescenční proteiny $x metabolismus $7 D049452
650    _2
$a HIV-proteasa $x genetika $x metabolismus $x účinky léků $7 D016333
650    _2
$a inhibitory HIV-proteasy $x farmakologie $7 D017320
650    _2
$a HeLa buňky $7 D006367
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a fluorescenční mikroskopie $7 D008856
650    _2
$a mutace $7 D009154
650    _2
$a fenotyp $7 D010641
650    _2
$a plazmidy $7 D010957
650    _2
$a rekombinantní fúzní proteiny $x metabolismus $7 D011993
650    _2
$a transfekce $7 D014162
650    _2
$a financování organizované $7 D005381
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Dantuma, Nico P.
700    1_
$a Lindsten, Kristina
700    1_
$a Masucci, Maria G.
700    1_
$a Konvalinka, Jan, $d 1963- $7 mzk2004208597
773    0_
$w MED00005010 $t Journal of clinical virology $g Roč. 36, č. 1 (2006), s. 50-59 $x 1386-6532
910    __
$a ABA008 $b x $y 9 $z 0
990    __
$a 20090312170439 $b ABA008
991    __
$a 20131014130354 $b ABA008
999    __
$a ok $b bmc $g 645016 $s 497932
BAS    __
$a 3
BMC    __
$a 2006 $b 36 $c 1 $d 50-59 $i 1386-6532 $m Journal of clinical virology $x MED00005010
GRA    __
$a NR8571 $p MZ0
LZP    __
$a 2009-B1/vtme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...